Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial

Lancet. 2025 Aug 16;406(10504):693-694. doi: 10.1016/S0140-6736(25)01440-0.

Authors

Alexander D Sherry¹, Stephanie O Dudzinski¹, Ethan B Ludmir²

Affiliations

¹ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: ebludmir@mdanderson.org.

PMID: 40818847
DOI: 10.1016/S0140-6736(25)01440-0

No abstract available

Publication types

Letter